Healthcare provider profile · identity verified

Catherine L Lowder, MD

Allopathic & Osteopathic Physicians|Internal Medicine · SAINT LOUIS, MO · NPI 1083614960

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Catherine L Lowder, MD received $35.73 in general payments during 2025 across 2 reported records.

Novo Nordisk Inc accounted for 56.1% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.

E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Eliquis by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$35.73

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$20.04	56.1%	1	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$15.69	43.9%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$35.73	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
Wegovy Normalized: wegovy	Drug	Novo Nordisk Inc	$20.04	1	2025
Source payment records 2025-08-10 · Novo Nordisk Inc · $20.04 · Open Payments source
ELIQUIS Normalized: eliquis	Drug	E.R. Squibb & Sons, L.L.C.	$15.69	1	2025
Source payment records 2025-09-19 · E.R. Squibb & Sons, L.L.C. · $15.69 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ELIQUIS eliquis	2025	Eliquis	2024	109	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713	Eliquis · 2024 Exact normalized brand match · 1 Part D row	109	25
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	46	suppressed by CMS
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Rybelsus open payments reported associated product	CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076	Rybelsus · 2024 Exact normalized brand match · 1 Part D row	17	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	613	159
Atorvastatin Calcium	Atorvastatin Calcium	524	140
Amlodipine Besylate	Amlodipine Besylate	482	142
Lisinopril	Lisinopril	438	124
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	398	84
Simvastatin	Simvastatin	344	98
Rosuvastatin Calcium	Rosuvastatin Calcium	335	101
Alprazolam	Alprazolam	307	87
Omeprazole	Omeprazole	287	82
Hydrochlorothiazide	Hydrochlorothiazide	278	78
Sertraline Hcl	Sertraline Hcl	264	72
Pantoprazole Sodium	Pantoprazole Sodium	256	84
Zolpidem Tartrate	Zolpidem Tartrate	253	60
Metoprolol Succinate	Metoprolol Succinate	216	66
Tramadol Hcl	Tramadol Hcl	208	57
Montelukast Sodium	Montelukast Sodium	199	58
Metformin Hcl	Metformin Hcl	195	60
Escitalopram Oxalate	Escitalopram Oxalate	194	60
Meloxicam	Meloxicam	164	51
Albuterol Sulfate Hfa	Albuterol Sulfate	159	47
Olmesartan Medoxomil	Olmesartan Medoxomil	159	49
Gabapentin	Gabapentin	157	53
Losartan Potassium	Losartan Potassium	147	50
Metoprolol Tartrate	Metoprolol Tartrate	145	38
Furosemide	Furosemide	143	50
Vitamin D2	Ergocalciferol (Vitamin D2)	141	40
Potassium Chloride	Potassium Chloride	130	46
Mounjaro	Tirzepatide	126	27
Trazodone Hcl	Trazodone Hcl	124	36
Duloxetine Hcl	Duloxetine Hcl	121	36
Fluticasone Propionate	Fluticasone Propionate	121	58
Eliquis	Apixaban	109	25
Clonazepam	Clonazepam	92	19
Glimepiride	Glimepiride	90	27
Carvedilol	Carvedilol	88	28
Bupropion Xl	Bupropion Hcl	87	26
Metformin Hcl Er	Metformin Hcl	76	22
Citalopram Hbr	Citalopram Hydrobromide	74	19
Clopidogrel	Clopidogrel Bisulfate	74	24
Paroxetine Hcl	Paroxetine Hcl	69	16
Warfarin Sodium	Warfarin Sodium	69	16
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	68	15
Wixela Inhub	Fluticasone Propion/Salmeterol	64	18
Oxycodone Hcl	Oxycodone Hcl	61	17
Tamsulosin Hcl	Tamsulosin Hcl	61	17
Ibuprofen	Ibuprofen	59	12
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	58	15
Pregabalin	Pregabalin	58	19
Pravastatin Sodium	Pravastatin Sodium	57	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	57	17
Atenolol	Atenolol	55	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	54	17
Finasteride	Finasteride	54	12
Allopurinol	Allopurinol	53	16
Lorazepam	Lorazepam	53	19
Lovastatin	Lovastatin	53	15
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	52	16
Prolia	Denosumab	51	34
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	50	17
Ezetimibe	Ezetimibe	47	14
Famotidine	Famotidine	47	15
Oxybutynin Chloride	Oxybutynin Chloride	47	14
Venlafaxine Hcl Er	Venlafaxine Hcl	47	suppressed
Ozempic	Semaglutide	46	suppressed
Donepezil Hcl	Donepezil Hcl	44	suppressed
Spironolactone	Spironolactone	44	15
Sumatriptan Succinate	Sumatriptan Succinate	44	suppressed
Tizanidine Hcl	Tizanidine Hcl	44	17
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	44	suppressed
Alendronate Sodium	Alendronate Sodium	43	suppressed
Methylprednisolone	Methylprednisolone	43	38
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	42	13
Januvia	Sitagliptin Phosphate	42	suppressed
Diclofenac Sodium	Diclofenac Sodium	41	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	41	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	40	suppressed
Buspirone Hcl	Buspirone Hcl	39	suppressed
Memantine Hcl	Memantine Hcl	39	suppressed
Mirtazapine	Mirtazapine	38	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	37	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	37	37
Diazepam	Diazepam	35	suppressed
Lansoprazole	Lansoprazole	34	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	34	11
Quetiapine Fumarate	Quetiapine Fumarate	34	suppressed
Celecoxib	Celecoxib	33	13
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	33	11
Fenofibrate	Fenofibrate	32	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	31	21
Temazepam	Temazepam	30	suppressed
Torsemide	Torsemide	30	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	27	suppressed
Meclizine Hcl	Meclizine Hcl	27	15
Ibandronate Sodium	Ibandronate Sodium	26	suppressed
Synthroid	Levothyroxine Sodium	26	suppressed
Amoxicillin	Amoxicillin	25	18
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	25	24
Zolpidem Tartrate Er	Zolpidem Tartrate	25	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	24	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	24	suppressed
Acyclovir	Acyclovir	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	23	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	23	suppressed
Clonidine Hcl	Clonidine Hcl	23	suppressed
Estradiol	Estradiol	23	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Testosterone	Testosterone	23	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	23	suppressed
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	22	22
Prednisone	Prednisone	22	15
Azithromycin	Azithromycin	21	18
Breo Ellipta	Fluticasone/Vilanterol	21	suppressed
Ipratropium Bromide	Ipratropium Bromide	21	suppressed
Klor-Con M20	Potassium Chloride	21	suppressed
Nystatin	Nystatin	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Verapamil Er	Verapamil Hcl	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	20	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Carisoprodol	Carisoprodol	19	suppressed
Cartia Xt	Diltiazem Hcl	19	suppressed
Glipizide	Glipizide	19	suppressed
Semglee (Yfgn)	Insulin Glargine-Yfgn	19	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	18	suppressed
Valsartan	Valsartan	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	13
Jardiance	Empagliflozin	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	suppressed
Rybelsus	Semaglutide	17	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	17	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	16	suppressed
Eszopiclone	Eszopiclone	16	suppressed
Fenofibrate	Fenofibrate,micronized	16	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	15	suppressed
Glipizide Er	Glipizide	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Risedronate Sodium	Risedronate Sodium	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Fluconazole	Fluconazole	14	suppressed
Folic Acid	Folic Acid	14	suppressed
Nebivolol Hcl	Nebivolol Hcl	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Nitroglycerin	Nitroglycerin	14	11
Ondansetron Odt	Ondansetron	14	suppressed
Rizatriptan	Rizatriptan Benzoate	14	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Bydureon Bcise	Exenatide Microspheres	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	13
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	13	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	13	suppressed
Estradiol-Norethindrone Acetat	Estradiol/Norethindrone Acet	13	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	12	suppressed
Carbamazepine Er	Carbamazepine	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Semglee (Yfgn) Pen	Insulin Glargine-Yfgn	12	suppressed
Sildenafil Citrate	Sildenafil Citrate	12	suppressed
Timolol Maleate	Timolol Maleate	12	suppressed
Armodafinil	Armodafinil	11	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	11	suppressed
Irbesartan	Irbesartan	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed
Raloxifene Hcl	Raloxifene Hcl	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$35.73 · 2 records	Novo Nordisk Inc	ELIQUIS, Wegovy	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Eliquis play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error